Gene, In-Vitro and In-Vivo - Clinical Research Informer

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

APRIL 14, 2023

All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models.

In-Vivo

In-Vivo Gene Therapy In-Vitro Engineer

Researchers reverse the in vitro and in vivo effects of the mutation that causes Stormorken syndrome

Medical Xpress

MAY 16, 2023

They study gene variation and mutations that cause rare genetic diseases. That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. A mutation is a permanent change in the genetic material.

In-Vitro

In-Vitro In-Vivo Genetic Disease Genetics

BioNTech shelves oral mRNA vaccine plans with Matinas

Pharmaceutical Technology

MAY 12, 2023

The in vivo study, conducted in mice, involved a phosphatidylserine-containing nano-formulation of mRNA supplied by BioNTech, distinct from traditional lipid nanocrystals (LNCs). Whilst the formulation had been successful in vitro , the oral administration in mice did not elicit activity.

Vaccination

Vaccination Vaccine In-Vivo In-Vitro

Merus’ Bizengri Gets FDA Accelerated Approval for NSCLC and Pancreatic Adenocarcinoma with NRG1 Gene Fusions

XTalks

DECEMBER 6, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Merus Bizengri (zenocutuzumab-zbco) for the treatment of metastatic non-small cell lung cancer (NSCLC) and advanced pancreatic adenocarcinoma with NRG1 gene fusions in patients who have had disease progression during or after prior systemic therapy. months to 16.6

Gene

Gene In-Vivo In-Vitro Genetics

CytoMed and MD Anderson partner to use gdTc for cancer treatment

Pharmaceutical Technology

MAY 10, 2023

The research teams will examine the use of CytoMed’s allogeneic gdTc on multiple AML and breast cancer subtypes in vitro and in vivo. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. The study aims to use AML cells and breast cancer cell lines from patients for evaluation.

Gene Therapy

Gene Therapy In-Vivo In-Vitro Gene

CohBar and Morphogenesis in merger for immuno-oncology therapies

Pharmaceutical Technology

MAY 24, 2023

It is building many MDSC-targeted, bi-functional ADCs for in vitro and in vivo characterisation, with lead selection expected by the end of next year. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Gene Therapy

Gene Therapy In-Vivo In-Vitro Immune Response

Could CRISPR cure HIV? US biotech Excision raises $60m to find out

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.

Gene Editing

Gene Editing In-Vivo DNA In-Vitro

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Gene Therapy

Gene Therapy Gene Development In-Vivo

FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)

FDA Law Blog

DECEMBER 6, 2024

Valentine On November 19, 2024, FDA released a draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. Section #1: FDA Interactions Given the wide range of sponsors (i.e., The draft guidance also describes pre-BLA meeting considerations, noting that FDA strongly recommends scheduling one.

Gene Therapy

Gene Therapy Gene Production In-Vivo

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

JANUARY 18, 2021

Angelman syndrome is a result of the missing or dysfunctional gene known as UBE3A. The gene is responsible for the normal and healthy development of an individual physically as well intellectually. Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system.

Marketing

Marketing Gene Drugs Protein

The Challenges and Promise of CAR T-Cell Therapy in Oncology

XTalks

SEPTEMBER 20, 2024

Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality. Such challenges highlight a significant unmet need and call for further advancements in the field.

Gene Editing

Gene Editing Manufacturing Gene In-Vivo

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

JANUARY 14, 2024

Usually, the desired gene, such as human insulin gene, when inserted into the plasmid of the host cell uses transcriptional and translational machinery of the host to express itself. It is worth mentioning that in vitro gene expression requires a suitable host for the production of a specific gene product.

Contract Manufacturing

Contract Manufacturing Protein Manufacturing Bacteria

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA

RNA Protein DNA In-Vivo

Bacteriophage Therapy – A Revolutionary Approach Towards Multi-Resistant Bacteria

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). These are mainly transmitted through air, water, living organisms, and food.

Bacteria

Bacteria Production In-Vivo In-Vitro

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Delveinsight

JANUARY 12, 2021

The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model. Bluebird spins off to two companies, cleaving off its gene therapy, and cancer units. Further, Birinapant also complements the anti-tumor activity of the immune system.

Licensing

Licensing Licensing Antibody Gene Therapy

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo

In-Vivo In-Vitro Antibody Development

Clinical Research Informer

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Researchers reverse the in vitro and in vivo effects of the mutation that causes Stormorken syndrome

Trending Sources

BioNTech shelves oral mRNA vaccine plans with Matinas

Merus’ Bizengri Gets FDA Accelerated Approval for NSCLC and Pancreatic Adenocarcinoma with NRG1 Gene Fusions

CytoMed and MD Anderson partner to use gdTc for cancer treatment

CohBar and Morphogenesis in merger for immuno-oncology therapies

Could CRISPR cure HIV? US biotech Excision raises $60m to find out

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

The Challenges and Promise of CAR T-Cell Therapy in Oncology

Biologics – The Next Step in Revolutionary Medication

What the Glycome Can Tell Us About Persistent HIV Infection

Bacteriophage Therapy – A Revolutionary Approach Towards Multi-Resistant Bacteria

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Stay Connected